LIVE WEBINAR: TARGATT™ Gene Insertion Technology For Safe And Efficacious iPSC-CAR-NK Cell Therapies – 06/28/22 | ASC

FREE Webinar: TARGATT™ Gene Insertion Technology For Safe and Efficacious iPSC-CAR-NK Cell Therapies 
Presenter: Ruby Tsai, Ph.D., President and CEO 
Date: June 28, 2022 
Time: 10 am PST 
Duration: 40 min (30 min & 10 min Q&A) 

Webinar Topics: 

1. TARGATT™ Master iPSC Platform
• Allogeneic Cell Products
• Safe and Efficient Gene Insertion TARGATT™ Technology
2. Application in iPSC-CAR-iNK Cell Therapy
• Site-specific Gene Insertion of Any CAR Gene of Interest
• Development of Allogenic CAR-iNK
• In Vitro and In Vivo Safety and Efficacy Studies
3. iPSC-NK GMP Manufacturing

The webinar will cover 3 topics: (1) an overview of unique site-specific, large cargo integration and iPSC platform, (2) application of the TARGATT™ Master iPSC Platform in CAR-NK cell therapy, (3) and ASC’s GMP cell banking and iPSC-NK manufacturing capabilities.

First, we will break down the technology used to establish the TARGATT™ Master iPSC line for targeted large-cargo integration. We will capture its application in the TARGATT™-iPSC Platform that can be used to safely and efficiently insert a single copy of your gene of interest (up to 20kb) at a safe harbor locus. With our multifaceted platform, the genetically modified iPS cells can be further differentiated into various cell types. Additionally, we will highlight the advantages of our technology over common methods. The second portion of the webinar will cover the cost-effective system that can be used to develop iPSC-CAR-iNK allogeneic products from the TARGATT™ Master iPS cells through several case studies. Lastly, we will present our GMP cell banking and iPSC manufacturing capabilities. ASC has received its Drug Manufacturing License from the California Food and Drug Branch and has put in place GMP-compliant manufacturing and quality procedures for iPSC manufacturing, including iPSC reprogramming, genome editing, differentiation, cell banking, and drug product manufacturing. In addition, we offer in vitro/animal safety and efficacy testing to support therapeutic cell product development.

Join ASC’s President and CEO, Ruby Tsai, on June 28 at 10 am PST to learn more about TARGATT™ and ASC’s GMP manufacturing capabilities.

About the Speaker:

Dr. Chen-Tsai received her PhD from Cornell University and did her post-doc research at Stanford University. She has been doing research in genome editing and stem cells for over 20 years. Prior to joining ASC, Dr. Chen-Tsai worked at Stanford University for 16 years as the Director of Transgenic Research Center and Associate Director of the Stanford Cancer Institute. Her most recent research at Stanford focused on using Parkinson patient-specific iPS cell lines, gene modification, and their differentiation to dopaminergic neurons as a disease model-in-a-dish. She is a co-inventor of the TARGATT™ integrase technology for site-specific gene insertion. Dr. Chen-Tsai is an author of many scientific papers and holder of over fifteen patents. Prior to becoming the CEO of Applied StemCell, Dr. Chen-Tsai led the ASC Therapeutics' gene/cell therapeutic product development for 5 years. She also led the successful filing of three pre-IND (one stem cell therapy, one gene therapy and one gene editing therapy) with the FDA.

About Applied StemCell, Inc.

Applied StemCell, Inc. (ASC) is a leading cell and gene therapy CRO/CDMO headquartered in California, USA. With over 13 years of iPSC and genome editing experience, Applied StemCell offers comprehensive research- and GMP-grade iPSC and gene editing solutions for the development of gene and cell products. We established a TARGATT™ master iPSC platform for safe and efficient, site-specific, and large cargo (up to 20kb) transgene integration (> 40% insertion efficiency without selection). This platform is currently used for the development of allogeneic iPSC-CAR-NK products. ASC is on a mission to assist in the development and manufacturing of novel therapeutics, and we seek to form partnerships focused on iPSC-based therapies.

Media Contact:
Maki Ogawa
Marketing Director, Applied StemCell, Inc.
408-773-8007
maki.ogawa@appliedstemcell.com